Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR

GlobeNewswire September 9, 2022

Ultragenyx to Participate at Citi BioPharma Conference

GlobeNewswire September 1, 2022

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 17, 2022

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 3, 2022

Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update

GlobeNewswire July 28, 2022

Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate Update

GlobeNewswire July 25, 2022

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 20, 2022

Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study

GlobeNewswire July 18, 2022

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets

GlobeNewswire July 14, 2022

Ultragenyx to Present at Goldman Sachs Global Healthcare Conference

GlobeNewswire June 10, 2022

Ultragenyx to Present at Jefferies Global Healthcare Conference

GlobeNewswire June 1, 2022

Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

GlobeNewswire May 19, 2022

Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics

GlobeNewswire May 17, 2022

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

GlobeNewswire May 9, 2022

Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update

GlobeNewswire May 5, 2022

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 3, 2022

Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference

GlobeNewswire May 3, 2022

Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update

GlobeNewswire April 27, 2022

Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report

GlobeNewswire April 25, 2022

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

GlobeNewswire April 22, 2022